BEAM (Beam Therapeutics) Minority Interest: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
71 GF Score
Price $27.63
GF Value $28.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Minority Interest?

Beam Therapeutics BEAM +1.43% 71 Minority Interest is $0.00 Mil as of Jun. 2026. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $28.11 (Fairly Valued). The stock has 4 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Beam Therapeutics's minority interest for the quarter that ended in Jun. 2026 was $0.00 Mil.

Beam Therapeutics Minority Interest Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Minority Interest Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BEAM
71GF Score
Beam Therapeutics Inc BEAM
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of $0.00 Mil mean?
Beam Therapeutics (BEAM) has a Minority Interest of $0.00 Mil as of Jun. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Beam Therapeutics.
Is Beam Therapeutics' Minority Interest too high?
Beam Therapeutics' current Minority Interest is $0.00 Mil. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Minority Interest compare to KOD and TARS?
Beam Therapeutics' Minority Interest of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Beam Therapeutics. Beam Therapeutics's current Minority Interest is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.63 — trading 1.7% below its estimated fair value. The current Minority Interest is $0.00 Mil. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current Minority Interest is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of $27.63 is trading 1.7% below its estimated GF Value™ of $28.11. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for BEAM:

  • Minority Interest: $0.00 Mil
  • GF Value™: $28.11 vs. price of $27.63 (1.7% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score

Get the complete analysis for BEAM

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.63
Price
$28.11
GF Value